Management of Fatigue in Patients with Advanced Cancer.
Patrick Charles StoneDiego Ezequiel CandelmiKerran KandolaLigia MonteroDom SmethamSahil SulemanAsanga FernandoRocío RojíPublished in: Current treatment options in oncology (2023)
Fatigue is a common and distressing symptom experienced by patients with cancer. It is most common in patients with locally advanced or metastatic incurable disease. It can have profound effects on quality-of-life and physical functioning. In addition to general supportive measures (directed at tackling contributory conditions and comorbidities), a variety of specific interventions have been developed which can be broadly categorised as physical therapies, psychological therapies or medication. There is some evidence that each of these approaches can have benefits in patients with earlier stage disease, those undergoing active treatment and in cancer survivors. The best evidence is for aerobic exercise, yoga, cognitive-behavioural therapy (CBT) and psycho-educational interventions. Less strong evidence supports the use of medications such as methylphenidate or ginseng. In patients with advanced disease, it is likely that the mechanisms of fatigue or the factors contributing to fatigue maintenance may be different. Relatively fewer studies have been undertaken in this group and the evidence is correspondingly weaker. The authors recommend the cautious use of aerobic exercise (e.g. walking) in those who are still mobile. The authors advise considering the use of psycho-educational approaches or CBT in those patients who are able to engage in such forms of therapy. In patients near the end-of-life, the authors advise use of dexamethasone (short-term use) and other pharmacological treatments only on the basis of a clinical trial.
Keyphrases
- physical activity
- sleep quality
- clinical trial
- advanced cancer
- squamous cell carcinoma
- palliative care
- locally advanced
- mental health
- small cell lung cancer
- healthcare
- young adults
- low dose
- end stage renal disease
- emergency department
- intellectual disability
- neoadjuvant chemotherapy
- rectal cancer
- patient reported outcomes
- autism spectrum disorder
- replacement therapy
- combination therapy
- electronic health record
- drug induced